{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:38:10Z","timestamp":1792269490770,"version":"4.4.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"DOI":"10.7759\/cureus.115193","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:56:21Z","timestamp":1787720181000},"source":"Crossref","is-referenced-by-count":1,"title":["Use of Rucaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma: A Case Report From a Tertiary Centre in India"],"prefix":"10.7759","author":[{"given":"Adhip","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Tilak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamim","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cells13131106","article-title":"Comprehensive review of uterine leiomyosarcoma: pathogenesis, diagnosis, prognosis, and targeted therapy","volume":"13","author":"Yang Q","year":"2024","unstructured":"Yang Q, Madueke-Laveaux OS, Cun H, Wlodarczyk M, Garcia N, Carvalho KC, Al-Hendy A. Comprehensive review of uterine leiomyosarcoma: pathogenesis, diagnosis, prognosis, and targeted therapy. Cells. 2024, 13:10.3390\/cells13131106","journal-title":"Cells"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D'Angelo E","year":"2010","unstructured":"D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010, 116:131-9. 10.1016\/j.ygyno.2009.09.023","journal-title":"Gynecol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061561","article-title":"Interrogating the genomic landscape of uterine leiomyosarcoma: a potential for patient benefit","volume":"14","author":"Dall GV","year":"2022","unstructured":"Dall GV, Hamilton A, Ratnayake G, Scott C, Barker H. Interrogating the genomic landscape of uterine leiomyosarcoma: a potential for patient benefit. Cancers (Basel). 2022, 14:10.3390\/cancers14061561","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-66-791-1009","article-title":"Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients","volume":"66","author":"Moskovic E","year":"1993","unstructured":"Moskovic E, MacSweeney E, Law M, Price A. Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients. Br J Radiol. 1993, 66:1009-15. 10.1259\/0007-1285-66-791-1009","journal-title":"Br J Radiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403394","article-title":"Doxorubicin-trabectedin with trabectedin maintenance in leiomyosarcoma","volume":"391","author":"Pautier P","year":"2024","unstructured":"Pautier P, Italiano A, Piperno-Neumann S, et al.. Doxorubicin-trabectedin with trabectedin maintenance in leiomyosarcoma. N Engl J Med. 2024, 391:789-99. 10.1056\/NEJMoa2403394","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki RG","year":"2007","unstructured":"Maki RG, Wathen JK, Patel SR, et al.. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007, 25:2755-63. 10.1200\/JCO.2006.10.4117","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0448","article-title":"BRCA1\/2 functional loss defines a targetable subset in leiomyosarcoma","volume":"24","author":"Seligson ND","year":"2019","unstructured":"Seligson ND, Kautto EA, Passen EN, et al.. BRCA1\/2 functional loss defines a targetable subset in leiomyosarcoma. Oncologist. 2019, 24:973-9. 10.1634\/theoncologist.2018-0448","journal-title":"Oncologist"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02687-0","article-title":"Targeting homologous recombination deficiency in uterine leiomyosarcoma","volume":"42","author":"Dall G","year":"2023","unstructured":"Dall G, Vandenberg CJ, Nesic K, et al.. Targeting homologous recombination deficiency in uterine leiomyosarcoma. J Exp Clin Cancer Res. 2023, 42:112. 10.1186\/s13046-023-02687-0","journal-title":"J Exp Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose M","year":"2020","unstructured":"Rose M, Burgess JT, O'Byrne K, Richard DJ, Bolderson E. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020, 8:564601. 10.3389\/fcell.2020.564601","journal-title":"Front Cell Dev Biol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.311","article-title":"PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: current practice and future directions","volume":"115","author":"Konecny GE","year":"2016","unstructured":"Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer. 2016, 115:1157-73. 10.1038\/bjc.2016.311","journal-title":"Br J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00402","article-title":"Phase II study of olaparib and temozolomide for advanced uterine leiomyosarcoma (NCI protocol 10250)","volume":"41","author":"Ingham M","year":"2023","unstructured":"Ingham M, Allred JB, Chen L, et al.. Phase II study of olaparib and temozolomide for advanced uterine leiomyosarcoma (NCI protocol 10250). J Clin Oncol. 2023, 41:4154-63. 10.1200\/JCO.23.00402","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2113-1","article-title":"A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation","volume":"71","author":"Plummer R","year":"2013","unstructured":"Plummer R, Lorigan P, Steven N, et al.. A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol. 2013, 71:1191-9. 10.1007\/s00280-013-2113-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00494","article-title":"Synthetic lethality beyond BRCA: a phase I study of rucaparib and irinotecan in metastatic solid tumors with homologous recombination-deficiency mutations beyond BRCA1\/2","volume":"8","author":"Tsang ES","year":"2024","unstructured":"Tsang ES, Dhawan MS, Pacaud R, et al.. Synthetic lethality beyond BRCA: a phase I study of rucaparib and irinotecan in metastatic solid tumors with homologous recombination-deficiency mutations beyond BRCA1\/2. JCO Precis Oncol. 2024, 8:e2300494. 10.1200\/PO.23.00494","journal-title":"JCO Precis Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/514714-use-of-rucaparib-plus-temozolomide-in-advanced-uterine-leiomyosarcoma-a-case-report-from-a-tertiary-centre-in-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:56:23Z","timestamp":1787720183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/514714-use-of-rucaparib-plus-temozolomide-in-advanced-uterine-leiomyosarcoma-a-case-report-from-a-tertiary-centre-in-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.115193","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}